Glynase MF (500/5 mg) Tablet is a combination medicine used for the treatment of type 2 diabetes mellitus. This medicine is not recommended for use in patients below 18 years of age.
It is product of USV. USV is a 55 year old leading healthcare company and No. 1 in the Oral Anti-Diabetic market. USV’s products are marketed globally to 75 countries. It also has a significant presence in the areas of Vitamins, Minerals, Nutrients, Dermatology, Gastroenterology and Neurology in India.
Diabetes type 2
Insulin is a hormone made by your pancreas that acts like a key to let blood sugar into the cells in your body for use as energy. If you have type 2 diabetes, cells don’t respond normally to insulin; this is called insulin resistance. Your pancreas makes more insulin to try to get cells to respond. Eventually your pancreas can’t keep up, and your blood sugar rises, setting the stage for prediabetes and type 2 diabetes. High blood sugar is damaging to the body and can cause other serious health problems, such as heart disease, vision loss, and kidney disease.
People are at risk for developing type 2 diabetes if they have prediabetes, are overweight, are 45 years or older, have a parent, brother, or sister with type 2 diabetes, are less physically active or had gestational diabetes (diabetes during pregnancy). It can be prevented or delayed with simple, proven lifestyle changes such as losing weight if you’re overweight, eating healthier, and getting regular physical activity.
Potentially Fatal: Glipizide: Hypoglycaemia in presence of renal or hepatic damage and alcohol. Metformin: Lactic acidosis in presence of renal failure and alcoholism.
Warnings and Precautions
There have been no clinical studies establishing conclusive evidence of macrovascular risk reduction with Glipizide and Metformin hydrochloride tablets or any other anti-diabetic drug.
Hypoglycaemia, stress, elderly. Thyroid impairment, monitor blood-glucose conc and renal function regularly.
Contraindicated in pregnancy and lactation
Glipizide + Metformin and Children- Safety and effectiveness of Glipizide and Metformin hydrochloride tablets in pediatric patients have not been established.
Glipizide + Metformin and Geriatic- Generally, elderly patients should not be titrated to the maximum dose of Glipizide and Metformin hydrochloride tablets
Hypersensitivity. Type 2 diabetes mellitus; ketoacidosis; severe renal or hepatic insufficiency, diabetic coma, cardiac failure, recent MI, CHF. IDDM; severe infection; acute or chronic metabolic acidosis with or without coma; stress, trauma; severe impairment of thyroid function; dehydration, acute or chronic alcoholism. Pregnancy, lactation.
Glipizide: Decreased effect with beta-blockers, cholestyramine, hydantoins, thiazide diuretics and urinary alkalinizers.
Metformin: Additive effect with sulphonylureas. Antagonistic effects with diuretics, corticosteroids, phenothiazines, thyroid products, oestrogens, oral contraceptives, phenytoin, nicotinic acid, sympathomimetics, Calcium channel blockers and isoniazid.
Potentially Fatal: Glipizide: Increased glipizide levels and effects with fluconazole, gemfibrozil, ketoconazole, NSAIDs, pioglitazone and sulfonamides. Increased hypoglycaemic effects with H2 antagonists, anticoagulants, androgens, cimetidine, salicylates, tricyclic antidepressants, probenecid, MAOIs, methyldopa, digitalis glycosides and urinary acidifiers.
Metformin: Lactic acidosis with alcohol and potentiation of hypoglycaemic effect. Cimetidine and furosemide may increase plasma-metformin levels. Drugs eliminated via renal tubular secretion may increase metformin levels.